Abstract
Background: Thin melanomas have become increasingly prevalent, and lesions 1 mm or less in thickness are frequently diagnosed. They are considered highly curable when treated with wide local excision alone with reported 5-year disease free survivals of 95% to 98%. However, thin Clark level III and IV melanomas may have an increased potential for metastasizing and late recurrence because of dermal lymphatics located at the interface of the papillary and reticular dermis. We have addressed this controversial area by reviewing the outcomes of patients with invasive thin (# 1.0 mm thick) melanomas.
Methods: We reviewed 415 invasive melanomas from 1983–1995 in the Rhode Island tumor registries which kept records of both tumor thickness and Clark levels. Sixty-eight (16.4%) of the 415 invasive melanomas were thin (# 1.0 mm in thickness) and were treated by wide local excision only. In situ lesions were excluded. Thirty-eight (56%) of the 68 thin melanomas were either Clark level III or IV.
Results: Seven (18.4%) of the 38 level III and IV thin melanomas had a recurrence at a minimum follow-up of 36 months. Median time to recurrence was 52 months, and the average measured depth of tumor thickness was 0.84 mm. Only one (3.3%) of 30 level II melanomas recurred (P < .05).
Conclusions: Thin level III and IV melanomas are at increased risk for late recurrence when compared with all thin melanomas. Because there is effective adjuvant therapy with alpha interferon for patients with stage III melanoma to treat regional and systemic disease, and because sentinel lymph node biopsy (SLNB) offers minimal morbidity, we suggest using SLNB to accurately stage and treat all patients with thin melanoma that are high Clark levels that are at increased risk for metastases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reintgen D, Balch CM, Kirkwood J, et al. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997;225: 1–14.
Parker SL, Tong T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1996;46:5–28.
Clark WH Jr., Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893–1904.
de Waal RM, van Altena MC, Erhard H, et al. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. Am J Path 1997;150: 1951–1957.
Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7–17.
Balch CM, Soong S-J, Bartolucci, AA. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255–266.
Morton DL, We DR, Wong JH, et al. Technical details of intra- operative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.
Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel node identification in patients with melanoma. Ann Surg 1996;223:217–24.
van der Spek-Keijser LM, van der Rhee HJ, Toth G, et al. Site, histological type, and thickness of primary cutaneous malignant melanoma in western Netherlands since 1980. Br J Dermatol 1997;136:565–71.
Veronesi U, Cascinelli N. Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438–441.
Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer 1986;57:545–548.
Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrences (15 years or longer) of cutaneous melanoma. Cancer 1997;79:2361–2370.
Balch CM, Song SJ, Shaw HM, et al. An analysis of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982;196:677–684.
Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous melanoma: Comparison of excision with margins of 1 of 3 cm. N Engl J Med 1988;318:1159–1162.
Breslow A. In search of thin lethal melanoma (editorial). Surg Gynecol Obstet 1976;143:799.
Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg 1983:198: 63–64.
Shaw HM, McCarthy WH, McCarthy SW, et al. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147– 1150.
Kelly JW, Sagebiel RW, Clyman S, et al. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg 1985;202:98 –103.
Slingluff C, Vollmer R, Reintgen D, et al. Lethal thin malignant melanoma. Ann Surg 1988;208:150–61.
Day CL, Mihm MC, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76 –1.69 mm in thickness. An appraisal of “thin” level IV lesions. Ann Surg 1982;195:30–34.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corsetti, R.L., Allen, H.M. & Wanebo, H.J. Thin #1 mm Level III and IV Melanomas Are Higher Risk Lesions For Regional Failure and Warrant Sentinel Lymph Node Biopsy. Ann Surg Oncol 7, 456–460 (2000). https://doi.org/10.1007/s10434-000-0456-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0456-4